Overview:
Small cell lung cancer (SCLC) remains a highly aggressive neuroendocrine carcinoma, comprising approximately 15% of all lung cancer cases. Despite advancements in treatment, outcomes remain poor, particularly for patients with extensive-stage disease, where median survival is often less than one year. Historically considered a homogeneous disease, recent molecular research has identified distinct subtypes with potential therapeutic implications, sparking interest in biomarker-driven treatment strategies. The integration of immunotherapy, targeted agents, and novel combination therapies is reshaping the SCLC treatment landscape, necessitating continued clinician education to optimize patient care.
To address this critical need, Cases & Conversations™: Expert Perspectives on Leveraging Recent Advances to Transform SCLC Treatment will be presented as a hybrid live satellite symposium during the 2025 IASLC Hot Topics in Basic and Translational Science: Small Cell Lung Cancer meeting in New York, NY. This interactive session will feature expert-led discussions, case-based learning, and a review of pivotal clinical trial data. By fostering a multidisciplinary dialogue, this program aims to equip healthcare professionals with the latest evidence-based strategies for integrating emerging therapies into routine clinical practice, ultimately improving outcomes for patients with SCLC.
Learning Objectives:
Upon completion of this activity, participants will be able to:
- Evaluate current and emerging clinical trial data on novel therapeutic strategies for the management of SCLC .
- Develop proactive approaches to anticipate, mitigate, and manage treatment-related adverse events in patients receiving SCLC therapy.
- Integrate evidence from clinical trials into real-world practice to optimize the use of SCLC treatments across different lines of care.

Jacob Sands, MD
Assistant Professor
Dana-Farber Cancer Institute
Harvard Medical School
Boston, MA

Anne Chiang, MD, PhD
Associate Professor of Medicine (Medical Oncology)
Associate Cancer Center Director, Clinical Initiatives
Yale School of Medicine
New Haven, CT

Alissa J. Cooper, MD
Assistant Attending
Thoracic Oncology Service
Memorial Sloan Kettering Cancer Center
New York, NY
Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Physicians’ Education Resource®, LLC, designates this live activity for a maximum of 1 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Physicians’ Education Resource®, LLC, is approved by the California Board of Registered Nursing, Provider #1666, for 1 Contact Hour.
Medical Oncologists (ABIM)

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

